3D Bioprinted perfusable and vascularized breast tumor model for dynamic screening of chemotherapeutics and CAR-T cells
M. Dey, M. H. Kim, M. Nagamine, M. Dogan, L. Kozhaya, D. Unutmaz, I. T. Ozbolat
Abstract
Despite substantial advancements in development of cancer treatments, lack of standardized and physiologically-relevant in vitro testing platforms limit the rapid and early screening of anti-cancer agents. A major barrier in this endeavor, is the complex interplay between the tumor microenvironment and host immune response and lack of predictive biomarkers for clinical benefit. To tackle this challenge, we have developed a dynamic-flow based three-dimensionally (3D) bioprinted vascularized breast tumor model, responding to chemo and immunotherapeutic treatments. Heterotypic tumor spheroids, comprising metastatic breast cancer cells (MDA-MB-231), human umbilical vein endothelial cells (HUVECs) and human dermal fibroblasts (HDFs), precisely bioprinted at pre-defined distances from a perfused vasculature, exhibited tumor angiogenesis and cancer invasion. Proximally bioprinted tumors ([~]100 m) exhibited enhanced capillary sprouting, anastomosis to perfused vasculature and increased cancer cell migration as compared to distally bioprinted spheroids ([~]500 m). Proximally bioprinted tumors treated with varying dosages of doxorubicin for 72 h enabled functional analysis of drug response, wherein, tumors portrayed a dose-dependent drug response behavior with [~]70% decrease in tumor volume for 1 M dose. Additionally, a cell based immune therapy approach was explored by perfusing HER2-targeting chimeric antigen receptor (CAR) modified CD8+ T cells for 24 or 72 h through the central vasculature. Extensive CAR-T cell recruitment to the endothelium and substantial T cell activation and infiltration in the tumor site, resulted in [~]70% reduction in tumor growth for high CAR treatment densities, after 72 h of treatment. The presented 3D model paves the way for a robust, precisely fabricated and physiologically-relevant 3D tumor microenvironment platform for future translation of anti-cancer therapies to personalized medicine for cancer patients. One Sentence SummaryA physiologically-relevant 3D bioprinted perfusable vascularized tumor model capable of dynamic screening of chemo and immunotherapeutics.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A high-throughput 3D bioprinted cancer cell migration and invasion model with versatile and broad biological applicability
M. Jung, J. Skhinas, … M. Kavallaris·bioRxiv·Dec 28, 2021
- Controlled tumor heterogeneity in a co-culture system by 3D bio-printed tumor-on-chip model
N. Moghimi, S. A. Hosseini, … M. Kohandel·bioRxiv·May 2, 2023
- Simulating the Tumor Microenvironment for Immune Cell Interactions via Deployable Extrusion Bioprinting
C. Mazzaglia, Y. Sheng, … Y. Y. S. Huang·bioRxiv·Apr 8, 2022
- 3D Microphysiological Tumor Model for Dual-Targeting CAR T Cell Immunotherapy
Xuan Peng, Željko Janićijević, … Larysa Baraban·Advanced SciencePeer-reviewed·Jul 24, 2025
- A novel in vitro 3D cancer model based on modular tissue engineering approach
Nima Daneshvar Baghbadorani, Mira Bosso, … Michael Dean Chamberlain·bioRxiv·Feb 25, 2025
- Freeform printing of heterotypic tumor models within cell-laden microgel matrices
T. G. Molley, G. K. Jalandhra, … K. A. Kilian·bioRxiv·Aug 30, 2020